DEF: Lineage Cell Therapeutics Seeks Shareholder Approval for Equity Incentive Plan Amendment, Director Elections and Auditor Ratification at 2025 Annual Meeting
Proxy Statement
Lineage Cell Therapeutics is holding its 2025 annual meeting to elect directors, ratify the auditor, approve executive compensation, and amend the equity incentive plan.
Summary
- Lineage Cell Therapeutics will hold its 2025 annual meeting of shareholders on June 26, 2025, in Carlsbad, CA.
- Shareholders will vote on the election of seven directors, ratification of Moss Adams LLP as the independent auditor, an advisory vote on executive compensation, and an amendment to the 2021 Equity Incentive Plan.
- The proposed amendment to the 2021 Equity Incentive Plan seeks to increase the number of common shares available by 19,500,000.
- The board of directors recommends voting for all director nominees and for Proposals 2, 3, and 4.
- The record date for determining shareholders eligible to vote is April 28, 2025.
- Shareholders can vote via the Internet, telephone, or mail.
Sentiment
Score: 7
Explanation: The document is primarily factual and procedural, outlining the agenda for the annual shareholder meeting. The tone is neutral and professional, with no significant positive or negative indicators. The company is seeking approval for routine matters and a share increase, which is generally a positive sign for future growth.
Positives
- The company is seeking to increase the number of shares available under its equity incentive plan, which can help attract and retain employees.
- The board is recommending a slate of experienced directors for election.
- The company is following good corporate governance practices by seeking shareholder ratification of the auditor appointment.
- The company is providing shareholders with an advisory vote on executive compensation.
Risks
- If the proposed amendment to the equity incentive plan is not approved, the company may have difficulty attracting and retaining employees.
- There is always a risk that shareholders will not support the board's recommendations on the various proposals.
Future Outlook
The company anticipates seeking shareholder approval of an increase in the number of shares available for Awards under the 2021 Plan in 2027.
Industry Context
Lineage Cell Therapeutics operates in the biotechnology industry, which is characterized by high levels of research and development spending and a long and uncertain regulatory approval process. The company's focus on cell therapies for serious neurological and ophthalmic conditions places it within a competitive landscape of other companies developing innovative treatments for these diseases.
Comparison to Industry Standards
- The peer group used for evaluating executive and director compensation includes companies like 4D Molecular Therapeutics, Cartesian Therapeutics, and Fate Therapeutics.
- These companies generally have fewer than 150 employees, market capitalization between $150 million and $750 million, and a lead development program in Phase 2.
- The stage of clinical development of Lineage and its peers renders them pre-commercial, so revenues were not a meaningful factor in selecting the peer group.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Don M. Bailey | NA | 2025-06-26 | Mr. Bailey requested not to be nominated for reelection |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amendment to Equity Incentive Plan | Increase the number of common shares available under the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan by 19,500,000. | 2025-06-26 | If approved, the company will have 34,968,280 shares available for grant under the 2021 Plan, plus the Prior Plan Returning Shares, as such shares become available from time to time. Absent any unforeseen circumstances, we anticipate seeking shareholder approval of an increase in the number of shares available for Awards under the 2021 Plan in 2027. |
Related Party Transactions
- Broadwood purchased 6,730,770 common shares in the offering, and Don M. Bailey, a member of our board of directors, purchased approximately 100,000 common shares in the offering.
- In January 2025, following receipt of stockholder approval of the issuance of our common shares and accompanying warrant pursuant to the terms of the securities purchase agreement between us and Broadwood, Broadwood purchased 7,894,737 common shares and an accompanying warrant to purchase an aggregate of up to 7,894,737 common shares.
Stakeholder Impact
- Shareholders will have the opportunity to vote on key corporate governance matters.
- Employees may benefit from the increased availability of equity awards.
- The company's ability to attract and retain talent could be enhanced by the approval of the equity incentive plan amendment.
Next Steps
- Shareholders need to vote on the proposals before the deadlines.
- The company will hold its annual meeting on June 26, 2025.
- The company will file the final voting results with the SEC.
Key Dates
| Date | Description |
|---|---|
| 2009-07 | Neal C. Bradsher, CFA became a director |
| 2014-10 | Michael H. Mulroy became a director |
| 2014-12 | Angus C. Russell became a director |
| 2018-09 | Brian M. Culley joined Lineage as Chief Executive Officer |
| 2018-09 | Brian M. Culley became a director |
| 2019-03 | Lineage acquired Asterias Biotherapeutics, Inc. |
| 2021-04 | Dipti Amin became a director |
| 2021-05 | Anula Jayasuriya became a director |
| 2021-07-21 | Date the 2021 Equity Incentive Plan was originally adopted by the Board of Directors |
| 2021-09-01 | George A. Samuel III joined Lineage as General Counsel and Corporate Secretary |
| 2021-09-13 | Date the 2021 Equity Incentive Plan was originally approved by the Shareholders |
| 2022-11-14 | Jill A. Howe joined Lineage as Chief Financial Officer |
| 2024-02-08 | Registered direct offering closed |
| 2024-03 | Michael H. Mulroy was appointed Chairman of the Board |
| 2024-07-01 | Cash fees for the Chair of the Board decreased from $100,000 to $90,000 and for the Chair of the Finance Strategy Committee decreased from $60,000 to $15,000 |
| 2025-01 | Broadwood purchased 7,894,737 common shares and an accompanying warrant |
| 2025-03 | Deborah Andrews appointed interim Chief Financial Officer of STAAR Surgical Company |
| 2025-04-18 | Date of information regarding beneficial ownership of common shares |
| 2025-04-28 | Record date for determining shareholders entitled to vote at the meeting |
| 2025-04-29 | Proxy materials first sent or made available to shareholders |
| 2025-05-21 | Warrant will be exercisable for one common share at an exercise price of $0.91 per common share |
| 2025-06-25 | Deadline for submitting votes via the Internet or telephone (11:59 p.m., Eastern Time) |
| 2025-06-26 | Annual meeting of shareholders |
| 2025-12-31 | Deadline for shareholders to notify the company of proposals for inclusion in next year's proxy materials |
| 2026-03-28 | Deadline for shareholders to give timely written notice regarding a proposal or nomination |
| 2026 | Next annual meeting of shareholders |
| 2027 | Anticipated date for seeking shareholder approval of an increase in the number of shares available for Awards under the 2021 Plan |
Keywords
annual meeting, proxy statement, directors, equity incentive plan, executive compensation, Moss Adams, shareholders, voting, Lineage Cell Therapeutics, corporate governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.